Myriad Genetics (MYGN) Return on Sales (2009 - 2026)

Myriad Genetics (MYGN) has reported Return on Sales for 18 consecutive years, with 0.0% the latest figure, recorded in Q1 2026.

• In Q1 2026, Return on Sales changed 0.0% year-over-year to 0.0%; the TTM figure through Mar 2026 stood at 0.0% (changed 0.0% YoY), while the FY2025 annual figure was 0.0%, changed 0.0% from the prior year.
• Return on Sales slipped to 0.0% in Q1 2026 per MYGN's latest filing, from 0.0% in the prior quarter.
• Across five years, Return on Sales topped out at 0.0% in Q1 2025 and bottomed at 0.02% in Q2 2025.
• Historically, Return on Sales has averaged 0.0% across 5 years, with a median of 0.0% in 2026.
• Annual changes were most pronounced in 2022 — Return on Sales changed 0 bps — and 2023, when it decreased 1 bps.
• Myriad Genetics' Return on Sales stood at 0.0% in 2022, then soared by 33 bps to 0.0% in 2023, then dropped by 27 bps to 0.0% in 2024, then jumped by 81 bps to 0.0% in 2025, then tumbled by 352 bps to 0.0% in 2026.
• Business Quant data shows MYGN's Return on Sales at 0.0% in Q1 2026, 0.0% in Q4 2025, and 0.0% in Q3 2025.